Stealth BioTherapeutics (MITO) Stock Surges 10%: It’s Leading In Retinal Mitochondrial Health

Stealth BioTherapeutics (MITO) is a biotechnology company working in the clinical stage and engaged in the discovery, development, and commercialization of new treatments for diseases associated with mitochondrial dysfunction. Weekly statistics show that its stock price has improved by 6%. On September 8, it cost $ 1.28. On Thursday, it surged $ 1.35. The price has remained stable until Tuesday, only fluctuating between $1.30 and $ 1.35. On Tuesday, it fell to $ 1.15, losing 15% in one day. However, after a sharp decline, it recovered with the same speed. The current trading price is $ 1.36.
MITO announced that this autumn there have been several abstracts for presentation at several major ophthalmic conferences. These abstracts indicate new clinical results from the ReCLAIM trial, which evaluated elamipretide in patients with dry AMD (age-related macular degeneration ), and also clinical updates from the ongoing ReCLAIM-2 study in patients with extrafoveal, or non-central, geographic atrophy (GA) due to dry AMD. GA is a progressive disease, which contributes to the loss of independence for affected people.


Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/zjrlrgmy/public_html/wp-includes/functions.php on line 5107